恶性黑色素瘤患者MGMT基因启动子甲基化研究

摘要

Objective This study was designed to investigate the association of MGMT promoter methylation and MGMT protein expression in Chinese malignant melanoma patients.Methods We analyzed the MGMT promoter methylation by methylation-specific polymerase chain reaction (MS-PCR) and protein expression by immunohistochemistry (IHC) in 44 malignant melanoma cases.Results We found that MGMT promoter hypermethylation occurred in 18 of 44 (40.9％ ) cases, MGMT protein expression rate of MGMT promoter methylation patients was 27.8％ (5/18) and MGMT protein expression rate of MGMT promoter unmethylation patients was 65.4％ (17/26).The presence of hypermethylation was associated with loss of MGMT protein (P = 0.014).Conclusion In the advanced malignant melanoma MGMT promoter methylation may reduce MGMT protein expression;the examination of MGMT promoter methylation status in melanoma may be useful for stratefying patients with melanoma into suitable chemotherapy such as alkylating agents, and offer theoretical and practical basis to personalized treatments.%目的 分析中国恶性黑色素瘤患者MGMT启动子甲基化水平和蛋白表达的关系.方法 通过MS-PCR方法检测44例恶性黑色素瘤患者MGMT启动子甲基化水平,免疫组化法检测MGMT蛋白的表达.结果 44例恶性黑色素瘤患者的MGMT启动子甲基化率为40.9%(18/44),MGMT启动子甲基化患者的MGMT蛋白表达率为27.8%(5/18),非甲基化患者的MGMT蛋白表达率为65.4%(17/26),MGMT启动子甲基化与MGMT蛋白的低表达有相关性(P=0.014).结论 在晚期恶性黑色素瘤中MGMT启动子甲基化可能降低MGMT蛋白的表达,提示可以通过分析晚期黑色素瘤患者MGMT基因启动子甲基化状态,预测患者对烷化剂类药物的敏感性,为实现个体化治疗提供理论和实践依据.